Lisaftoclax launched as China's first Bcl-2 inhibitor in CLL/SLL; the thesis turns on NRDL inclusion and commercial ramp against venetoclax's global dominance

Ascentage Pharma is a commercial-stage biopharmaceutical company whose lead product treats chronic lymphocytic leukemia and small lymphocytic lymphoma and is now approved in China.

Lisaftoclax, a Bcl-2 inhibitor approved in China for BTK inhibitor-pretreated CLL/SLL, is the company's first commercial-stage hematology asset with $10.1M in revenue over its first five months. The thesis depends on whether NRDL reimbursement inclusion drives a step-change in patient uptake sufficient to scale revenue toward the $177.7M annual operating loss. AbbVie and Genentech's venetoclax, the global Bcl-2 inhibitor standard, sets a high bar for differentiation, and any regulatory delay in NRDL listing would prolong the cash consumption trajectory.